摘要
前言:阿尔茨海默病是一种慢性疾病,考虑到60岁以上的人群,估计发病率约为10-30%。大多数患者(>95%)呈散发型,以晚发(80~90岁)为特征,这是脑间隙无法清除淀粉样蛋白(β,Aβ)肽的结果。对散发性疾病的遗传危险因素进行了大量的研究。一些现有的治疗阿尔茨海默氏病的药物可提供长达12个月的症状治疗,但目前还没有经过批准的疾病修饰疗法。在这一条线上,一种基于重新定位药物的补充策略(这些药物被批准用于其他疾病的治疗)可能是令人感兴趣的。值得注意的是,一些临床试验表明,有几类药物对阿尔茨海默病的治疗具有强大和有益的作用。在目前的工作中,我们介绍了这些替代治疗的细节和评估。它强调了几种具有相关证据的化合物,这些化合物值得进一步研究,以便在阿尔茨海默病患者的临床试验中澄清最佳的治疗条件。
关键词: 阿尔茨海默病,神经变性,药物重新定位,τ蛋白,淀粉样蛋白-β肽,药效团。
Current Alzheimer Research
Title:Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives
Volume: 15 Issue: 12
关键词: 阿尔茨海默病,神经变性,药物重新定位,τ蛋白,淀粉样蛋白-β肽,药效团。
摘要: Introduction: Alzheimer's disease is known to be a chronic disease, with an estimated prevalence of about 10-30%, considering the population over 60 years of age. Most patients with this disorder (> 95%) present the sporadic form, being characterized by a late onset (80-90 years of age), and it is the consequence of the failure to clear the amyloid-β (Aβ) peptide from the interstices of the brain. Significant numbers of genetic risk factors for the sporadic disease have been researched. Some existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease- modifying therapies. In this line, a complementary strategy based on repositioning drugs which are approved for the treatment of other disorders could be interesting. It is noteworthy the fact that some clinical trials indicate that several classes of drugs own potent and beneficial effects on the Alzheimer's disease treatment. In this present work, we present the details and evaluation of these alternative treatments. It has highlighted several compounds with relevant evidence for this purpose, which deserves further investigation to clarify optimal treatment conditions in the clinical trials of patients with Alzheimer's disease.
Export Options
About this article
Cite this article as:
Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives, Current Alzheimer Research 2018; 15 (12) . https://dx.doi.org/10.2174/1567205015666180813150703
DOI https://dx.doi.org/10.2174/1567205015666180813150703 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Strategies for Potentiation and Facilitation of Antidepressant Treatment: Introduction
Current Drug Targets Myelination in Bipolar Patients and the Effects of Mood Stabilizers on Brain Anatomy
Current Pharmaceutical Design Presynaptic Cell Dependent Modulation of Inhibition in Cortical Regions
Current Neuropharmacology Neurotransmitters and Behavioral Alterations Induced by Nickel Exposure
Endocrine, Metabolic & Immune Disorders - Drug Targets The Importance of Citicoline in Combined Treatment in Dementia: What did the Citimem Study Teach us?
Reviews on Recent Clinical Trials Factors Associated with HIV Virologic Failure Among Patients on HAART for One Year at Three Sentinel Surveillance Sites in China
Current HIV Research Lessons Learned from Muscle Fatigue: Implications for Treatment of Patients with Hyperkalemic Periodic Paralysis
Recent Patents on Biotechnology Myogenic Properties of Brain and Cardiac Vessels and their Relation to Disease
Current Vascular Pharmacology NGF and BDNF Alterations by Prenatal Alcohol Exposure
Current Neuropharmacology Chemistry, Physiology, and Pharmacology of β-Adrenergic Mechanisms in the Heart. Why are β-Blocker Antiarrhythmics Superior?
Current Pharmaceutical Design Regulation of GABA Neurotransmission by Glutamic Acid Decarboxylase (GAD)
Current Pharmaceutical Design Patterns of Cognitive Decline and Rates of Conversion to Dementia in Patients with Degenerative and Vascular forms of MCI
Current Alzheimer Research α-Synuclein Aggregation
Protein & Peptide Letters Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Evaluation of Salivary Antioxidants and Oxidative Stress Markers in Male Smokers
Combinatorial Chemistry & High Throughput Screening Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development§
Current Medicinal Chemistry Effect of Various Classes of Pesticides on Expression of Stress Genes in Transgenic C. elegans Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Biophysics of Parkinsons Disease: Structure and Aggregation of α- Synuclein
Current Protein & Peptide Science The Cellular Electrophysiologic Effect of A New Amiodarone Like Antiarrhythmic Drug GYKI 16638 in Undiseased Human Ventricular Muscle: Comparison With Sotalol And Mexiletine
Current Medicinal Chemistry AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets